# OnCo record cml-advanced-phase (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cml-advanced-phase/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cml-advanced-phase" ;
  schema:name "Chronic myeloid leukaemia, accelerated and blast phase"@en ;
  schema:alternateName "CML-AP"@en, "CML-BP"@en, "Blast crisis"@en, "Advanced-phase CML"@en, "Accelerated-phase CML"@en ;
  schema:description "Chronic myeloid leukaemia can accelerate and then transform into an acute leukaemia called blast crisis. Tyrosine kinase inhibitors are given at full strength, combined with acute leukaemia chemotherapy in blast phase, to bring the disease back to chronic phase quickly enough for a donor stem cell transplant, the only treatment that cures it."@en ;
  schema:url <https://onco.cc/cancers/cml-advanced-phase/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytogenetics-fish/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:pathways <https://onco.cc/pathways/bcr-abl1-signalling/> ;
  onco:terms <https://onco.cc/terms/blasts/>, <https://onco.cc/terms/philadelphia-chromosome/>, <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/resistance/> ;
  onco:pipeline <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/olverembatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/nct04233346/>, <https://onco.cc/trials/nct06514534/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:standardOfCare <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/olverembatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/trials/nct04233346/>, <https://onco.cc/trials/nct06514534/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/terms/conditioning-regimen/> .